Trial · NCT01096849
Results by group83
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 83
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Patients Who Attained Microbiological Eradication (MBE) at the Test of Cure (TOC) Visit in the Microbiological Intent to Treat (MITT) Population | Plazomicin (10 mg/kg) | 50 | 95% Confidence Interval 21.1 to 78.9 | percentage of patients | |
| Percentage of Patients Who Attained Microbiological Eradication (MBE) at the Test of Cure (TOC) Visit in the Microbiological Intent to Treat (MITT) Population | Plazomicin (15 mg/kg) | 60.8 | 95% Confidence Interval 46.1 to 74.2 | percentage of patients | |
| Percentage of Patients Who Attained Microbiological Eradication (MBE) at the Test of Cure (TOC) Visit in the Microbiological Intent to Treat (MITT) Population | Levofloxacin | 58.6 | 95% Confidence Interval 38.9 to 76.5 | percentage of patients | |
| Percentage of Patients Who Attained MBE at the TOC Visit in the Microbiologically Evaluable (ME) Population | Plazomicin (10 mg/kg) | 85.7 | 95% Confidence Interval 42.1 to 99.6 | percentage of patients | |
| Percentage of Patients Who Attained MBE at the TOC Visit in the Microbiologically Evaluable (ME) Population | Plazomicin (15 mg/kg) | 88.6 | 95% Confidence Interval 73.3 to 96.8 | percentage of patients | |
| Percentage of Patients Who Attained MBE at the TOC Visit in the Microbiologically Evaluable (ME) Population | Levofloxacin | 81.0 | 95% Confidence Interval 58.1 to 94.6 | percentage of patients | |
| Percentage of Patients With Treatment-Emergent Adverse Events (TEAE) | Plazomicin (10 mg/kg) | 31.8 | percentage of patients | ||
| Percentage of Patients With Treatment-Emergent Adverse Events (TEAE) | Plazomicin (15 mg/kg) | 35.1 | percentage of patients | ||
| Percentage of Patients With Treatment-Emergent Adverse Events (TEAE) | Levofloxacin | 47.7 | percentage of patients | ||
| Percentage of Patients Who Attained Clinical Cure Based on Investigator and Sponsor Assessments at TOC Visit in the Intent-to-treat (ITT) Population | Plazomicin (10 mg/kg) | Investigator's Assessment: Cured | 63.6 | 95% Confidence Interval 40.7 to 82.8 | percentage of patients |
| Percentage of Patients Who Attained Clinical Cure Based on Investigator and Sponsor Assessments at TOC Visit in the Intent-to-treat (ITT) Population | Plazomicin (15 mg/kg) | Investigator's Assessment: Cured | 69.7 | 95% Confidence Interval 58.1 to 79.8 | percentage of patients |
| Percentage of Patients Who Attained Clinical Cure Based on Investigator and Sponsor Assessments at TOC Visit in the Intent-to-treat (ITT) Population | Levofloxacin | Investigator's Assessment: Cured | 70.2 | 95% Confidence Interval 55.1 to 82.7 | percentage of patients |
| Percentage of Patients Who Attained Clinical Cure Based on Investigator and Sponsor Assessments at TOC Visit in the Intent-to-treat (ITT) Population | Plazomicin (10 mg/kg) | Sponsor's Assessment: Cured | 59.1 | 95% Confidence Interval 36.4 to 79.3 | percentage of patients |
| Percentage of Patients Who Attained Clinical Cure Based on Investigator and Sponsor Assessments at TOC Visit in the Intent-to-treat (ITT) Population | Plazomicin (15 mg/kg) | Sponsor's Assessment: Cured | 69.7 | 95% Confidence Interval 58.1 to 79.8 | percentage of patients |
| Percentage of Patients Who Attained Clinical Cure Based on Investigator and Sponsor Assessments at TOC Visit in the Intent-to-treat (ITT) Population | Levofloxacin | Sponsor's Assessment: Cured | 68.1 | 95% Confidence Interval 52.9 to 80.9 | percentage of patients |
| Percentage of Patients Who Attained Clinical Cure Based on Investigator and Sponsor Assessments at the TOC Visit in the CE Population | Plazomicin (10 mg/kg) | Investigator's Assessment: Cured | 66.7 | 95% Confidence Interval 41.0 to 86.7 | percentage of patients |
| Percentage of Patients Who Attained Clinical Cure Based on Investigator and Sponsor Assessments at the TOC Visit in the CE Population | Plazomicin (15 mg/kg) | Investigator's Assessment: Cured | 76.6 | 95% Confidence Interval 64.3 to 86.2 | percentage of patients |
| Percentage of Patients Who Attained Clinical Cure Based on Investigator and Sponsor Assessments at the TOC Visit in the CE Population | Levofloxacin | Investigator's Assessment: Cured | 78.6 | 95% Confidence Interval 63.2 to 89.7 | percentage of patients |
| Percentage of Patients Who Attained Clinical Cure Based on Investigator and Sponsor Assessments at the TOC Visit in the CE Population | Plazomicin (10 mg/kg) | Sponsor's Assessment: Cured | 66.7 | 95% Confidence Interval 41.0 to 86.7 | percentage of patients |
| Percentage of Patients Who Attained Clinical Cure Based on Investigator and Sponsor Assessments at the TOC Visit in the CE Population | Plazomicin (15 mg/kg) | Sponsor's Assessment: Cured | 76.6 | 95% Confidence Interval 64.3 to 86.2 | percentage of patients |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01096849/results